The Claim

Implemented Most Favored Nation drug pricing, securing deals with 16 of the world’s largest pharmaceutical companies to guarantee Americans pay the same low prices other developed nations receive.

The Claim, Unpacked

What is literally being asserted?

Three factual assertions: (1) the administration “implemented” Most Favored Nation drug pricing as policy, (2) it secured deals with 16 major pharmaceutical companies, and (3) these deals “guarantee” that Americans pay the same low prices as other developed nations. The word “guarantee” is the strongest claim — it implies a binding, enforceable arrangement that produces price parity for American consumers.

What is being implied but not asserted?

That all Americans — insured and uninsured — are now paying prices comparable to those in countries like Germany, the UK, or Japan. That these are binding, permanent arrangements. That this represents a structural transformation of the U.S. pharmaceutical pricing system. That prior administrations failed where this one succeeded.

What is conspicuously absent?

That the deals are voluntary, not mandatory. That the tariff leverage used to secure them (Section 232 threats) has been legally undermined by the Supreme Court’s February 2026 IEEPA ruling. That the deals primarily affect a narrow population — uninsured cash-paying patients and Medicaid enrollees — not the roughly 85% of Americans with insurance. That all 16 companies raised list prices on hundreds of drugs in January 2026, weeks after signing the deals. That the Biden administration’s Inflation Reduction Act created a mandatory drug negotiation program — now in its second round — that produces legally binding price reductions for Medicare, and that the Trump administration continued rather than replaced this program. That the first-term attempt at MFN pricing was struck down by three federal courts in 2020.

Evidence Assessment

Established Facts

The administration signed an MFN executive order and secured voluntary agreements with 16 companies. On May 12, 2025, President Trump signed Executive Order 14297, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” directing HHS to communicate MFN price targets to manufacturers within 30 days. Between September 30, 2025 and December 19, 2025, 16 companies signed voluntary agreements: Pfizer (September 30), AstraZeneca (October 10), EMD Serono (October 16), Novo Nordisk and Eli Lilly (November 6), followed by Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi (December 19). Two additional companies signed in the interim period. ¹

The deals are voluntary, not mandatory, and were secured through tariff leverage. Each manufacturer agreed to terms in exchange for three-year exemptions from potential Section 232 pharmaceutical tariffs. The Commerce Department opened a Section 232 investigation into pharmaceutical imports on April 1, 2025. On September 25, 2025, Trump announced a threatened 100% tariff on branded pharmaceutical imports. This tariff threat — not statutory authority — was the primary enforcement mechanism. Deal terms vary by company but generally include: MFN pricing for state Medicaid programs, discounts on select drugs through TrumpRx.gov for uninsured cash-paying patients, pledges to launch new drugs at comparable prices in developed nations, and U.S. manufacturing investment commitments. ²

All 16 companies raised list prices on hundreds of drugs in January 2026. In the first two weeks of 2026, the 16 signatory companies raised list prices on 872 brand-name drugs — including drugs for cancer, heart failure, Type 2 diabetes, and COVID. The median increase was 4%, matching the 2025 rate. Pfizer alone raised prices on 72 products, including a 15% increase on its COVID vaccine. Companies defended this by distinguishing list prices from net prices after rebates, but for uninsured consumers and those with high-deductible plans, list prices are frequently the prices they pay. ³

The Biden administration’s IRA drug negotiation program — which the Trump administration continued — produces larger, mandatory savings. The Inflation Reduction Act of 2022 created a legally binding Medicare drug price negotiation program. The first round of 10 negotiated drugs took effect January 1, 2026, with price reductions ranging from 38% to 79% off list prices, saving Medicare an estimated $6 billion annually and beneficiaries $1.5 billion in out-of-pocket costs. A second round covering 15 additional drugs (including Ozempic and Wegovy) was announced in November 2025 for 2027, with estimated savings of $12 billion annually. The Trump administration continued this program rather than dismantling it. ⁴

The first-term MFN attempt was struck down by three federal courts. In 2020, the Trump administration issued an MFN interim final rule targeting 50 Medicare Part B drugs, bypassing notice-and-comment procedures. Three federal courts blocked it: the U.S. District Court for the District of Maryland (December 23, 2020), and the Southern District of New York and Northern District of California shortly thereafter. The courts found no “good cause” for emergency implementation, noting that CMS “was aware of this problem for years and failed to act.” CMS withdrew the rule. ⁵

Strong Inferences

Americans are not paying “the same low prices” as other developed nations. The claim’s central assertion — price parity — is not supported by available evidence. Trump stated in January 2026 that “we now are paying the lowest price anywhere in the world for drugs.” When pressed, a White House spokesperson clarified this was aspirational — Americans “are going to be paying the same if not lower.” Health economist Rena Conti (Boston University) stated the deals “don’t appear to have translated into actual savings for people at the pharmacy counter or for public or commercial payers yet.” International price comparisons remain unverifiable: the administration confirmed comparing against G7 nations but did not specify which prices or account for international rebates. ⁶

The deals primarily benefit a narrow subset of Americans, not the general population. TrumpRx.gov, launched February 5, 2026, lists 54 drugs from five manufacturers — out of more than 24,000 FDA-approved prescription drugs. It targets uninsured cash-paying patients, approximately 8% of the U.S. population. KFF analysis found that at least 17 of the 22 brand-name drugs with generic equivalents on TrumpRx are available more cheaply through GoodRx or Cost Plus Drugs. The platform relies on GoodRx’s pricing data and technology. As of March 2026, only 7% of prescription drug users had visited TrumpRx to compare prices. For the 85% of Americans with insurance, the deals do not directly address commercial drug affordability. ⁷

The “discounts” are calculated off list prices, which are not what most Americans pay. The TrumpRx discounts of 50-93% are measured against manufacturers’ list prices. However, most insured Americans already pay net prices after rebates and insurance negotiations. Average discounts on brand-name drugs in Medicare Part D are already approximately 40% off list; Medicaid already negotiates prices 65% lower than Part D. Health policy experts noted that TrumpRx prices “are unlikely to be lower than net prices commercial plans were already negotiating” for many of the listed drugs. This means the headline discount percentages substantially overstate the actual savings relative to what patients and payers were already paying. ⁸

The tariff leverage underpinning the deals faces legal uncertainty. The Supreme Court’s February 20, 2026 ruling in Learning Resources, Inc. v. Trump struck down IEEPA-based tariffs 6-3. While this ruling did not directly invalidate Section 232 tariffs (which rest on separate statutory authority), it demonstrated judicial willingness to constrain executive tariff power. The Section 232 pharmaceutical investigation had not yet resulted in formal tariff proclamation as of the ruling. The three-year tariff exemptions that anchored the MFN deals may become less valuable if the threatened tariffs never materialize or face their own legal challenges. ⁹

The deals run only three years and lack codification in law. SEC filings reviewed by STAT News revealed that at least some MFN agreements run only three years. The deals are executive agreements, not statutory programs. No legislation codifying MFN drug pricing has been enacted. CRS analysis found that the 2025 EO “neither defines ‘MFN price’ nor provides any instruction as to how the Secretary should calculate the MFN price” and identified no clear statutory authority for imposing MFN pricing on private markets. ¹⁰

What the Evidence Shows

The claim contains a factual core: the administration did sign an MFN executive order and negotiated voluntary agreements with 16 pharmaceutical companies. These agreements represent genuine policy activity and, for certain narrow populations, real price reductions on specific drugs. The Medicaid MFN pricing provisions and the TrumpRx discounts for uninsured patients on GLP-1 drugs and fertility treatments are meaningful for those individuals.

However, the claim’s framing — that MFN pricing has been “implemented” and that Americans are “guaranteed” the “same low prices” as other developed nations — is not supported by the evidence on multiple fronts. First, the deals are voluntary agreements secured through tariff threats, not implemented policy with statutory backing. The first-term attempt at mandatory MFN pricing was struck down by three federal courts, and the current executive order lacks defined pricing methodology, clear legal authority, or enforcement mechanisms beyond the tariff lever — which itself faces post-SCOTUS uncertainty. Second, all 16 companies raised list prices on hundreds of drugs immediately after signing, and the median annual price increase rate did not change. Third, the TrumpRx platform covers 54 of more than 24,000 FDA-approved drugs, targets the roughly 8% of Americans without insurance, and often offers prices higher than generics available through existing platforms like GoodRx and Cost Plus Drugs.

The claim also omits the larger drug pricing achievement operating in parallel: the Biden-era IRA Medicare Drug Price Negotiation Program, which the Trump administration continued. The IRA program produces mandatory, legally binding price reductions with estimated annual savings of $6-12 billion for Medicare — a structural reform with statutory enforcement, in contrast to voluntary three-year agreements. For the drug Eliquis, the IRA-negotiated Medicare price of $231 is substantially lower than the MFN direct-to-consumer price of $346.

The use of “guarantee” is particularly misleading. The deals contain no binding guarantee of international price parity. When the White House was asked whether Americans are actually paying the same prices as other countries, the spokesperson pivoted to a future tense: Americans “are going to be.” Independent verification of the international price comparison is not possible because deal terms remain largely confidential and international pricing structures involve country-specific rebates that are not publicly disclosed.

The Bottom Line

The administration did negotiate voluntary agreements with 16 pharmaceutical companies, and these deals provide some real savings for specific populations — particularly uninsured patients seeking GLP-1 drugs, insulin, and fertility treatments through TrumpRx. This is a genuine, if modest, accomplishment for that narrow group.

But describing these deals as “implemented Most Favored Nation drug pricing” that “guarantees” Americans pay the “same low prices” as other developed nations is not accurate. The agreements are voluntary, not implemented policy. They are three-year deals, not permanent structural reform. They primarily affect uninsured cash-paying patients and Medicaid enrollees, not the 85% of insured Americans. All 16 companies raised prices on hundreds of drugs immediately after signing. The headline discounts are measured against list prices that most Americans do not pay. International price parity has not been achieved or verified. And the tariff leverage that secured these deals now operates in a more constrained legal environment following the Supreme Court’s tariff ruling. The most substantial drug pricing reform currently operating — the IRA’s mandatory Medicare negotiation program — was enacted by the prior administration and continued, not created, by this one.

Footnotes

1. White House, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” May 12, 2025. https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/ ; White House, “Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients,” December 19, 2025. https://www.whitehouse.gov/fact-sheets/2025/12/fact-sheet-president-donald-j-trump-announces-largest-developments-to-date-in-bringing-most-favored-nation-pricing-to-american-patients/ ; Mintz, “Pharmaceutical Policy in Motion Continued: Trump Inks Nine New Drug Pricing Deals,” December 23, 2025. https://www.mintz.com/insights-center/viewpoints/2146/2025-12-23-pharmaceutical-policy-motion-continued-trump-inks-nine ↩

2. Jones Day, “Most Favored Nation Drug Pricing and Manufacturer Agreements,” December 2025. https://www.jonesday.com/en/insights/2025/12/most-favored-nation-drug-pricing-and-manufacturer-agreements ; Mintz, “A Pivotal Week for Pharmaceutical Policy,” October 7, 2025. https://www.mintz.com/insights-center/viewpoints/2146/2025-10-07-pivotal-week-pharmaceutical-policy-trump-administration ; Mintz, “Pharmaceutical Policy in Motion: Updates on the Trump Administration’s Drug Pricing Initiatives,” November 13, 2025. https://www.mintz.com/insights-center/viewpoints/2146/2025-11-13-pharmaceutical-policy-motion-updates-trump ↩

3. NPR, “Trump struck deals with 16 drug companies. But they’re still raising prices this year,” January 16, 2026. https://www.npr.org/2026/01/16/nx-s1-5678915/trumprx-pharma-drug-price-deals-list-prices ↩

4. Georgetown CHIR Medicare Policy Initiative, “Drug Pricing in the Era of Trump 2.0.” https://medicare.chir.georgetown.edu/drug-pricing-in-the-era-of-trump-2-0/ ; Medicare Rights Center, “Negotiated Prices Take Effect for Ten Drugs in 2026,” October 9, 2025. https://www.medicarerights.org/medicare-watch/2025/10/09/negotiated-prices-take-effect-for-ten-drugs-in-2026 ; KFF, “Understanding the Trump Administration’s Negotiated Drug Prices for Medicare.” https://www.kff.org/quick-take/understanding-the-trump-administrations-negotiated-drug-prices-for-medicare/ ↩

5. CRS Legal Sidebar LSB11319, “Most-Favored-Nation Prescription Drug Pricing Executive Order: Legal Issues.” https://www.congress.gov/crs-product/LSB11319 ↩

6. FactCheck.org, “Trump Misleads on Drug Pricing Deals,” February 2026. https://www.factcheck.org/2026/02/trump-misleads-on-drug-pricing-deals/ ↩

7. KFF, “TrumpRx: What’s the Value for Customers?” February 2026. https://www.kff.org/patient-consumer-protections/trumprx-whats-the-value-for-customers/ ; NBC News, “TrumpRx isn’t doing much for drug prices. What would it take to change that?” March 2026. https://www.nbcnews.com/health/health-news/trumprx-isnt-much-drug-prices-take-change-rcna263944 ↩

8. Georgetown CHIR, “Drug Pricing in the Era of Trump 2.0.” https://medicare.chir.georgetown.edu/drug-pricing-in-the-era-of-trump-2-0/ ; FactCheck.org, “Trump Misleads on Drug Pricing Deals,” February 2026. https://www.factcheck.org/2026/02/trump-misleads-on-drug-pricing-deals/ ↩

9. SCOTUSblog, “Supreme Court strikes down tariffs,” February 20, 2026. https://www.scotusblog.com/2026/02/supreme-court-strikes-down-tariffs/ ; Supreme Court, 24-1287 Learning Resources, Inc. v. Trump. https://www.supremecourt.gov/opinions/25pdf/24-1287_4gcj.pdf ↩

10. STAT News, “Trump’s MFN drug pricing deals run 3 years, some companies say,” February 27, 2026. https://www.statnews.com/2026/02/27/trump-drug-prices-pharma-mfn-deals-3-year-terms/ ; CRS Legal Sidebar LSB11319, “Most-Favored-Nation Prescription Drug Pricing Executive Order: Legal Issues.” https://www.congress.gov/crs-product/LSB11319 ↩